Eli Lilly (LLY) Depreciation and Depletion (2014 - 2015)
Eli Lilly (LLY) reported Depreciation and Depletion of $216.6 million for Q2 2015, little changed on a YoY basis from $216.3 million in Q2 2014, and up 1197.01% quarter-over-quarter from $16.7 million in Q1 2015.
Eli Lilly (LLY) Depreciation and Depletion (2014 - 2015) Analysis & Trends
Eli Lilly has reported Depreciation and Depletion for 2 years, with the latest figure at $216.6 million in Q2 2015.
- For the quarter ending Q2 2015, Depreciation and Depletion changed 0.14% year-over-year to $216.6 million; the trailing twelve-month figure through Jun 2015 stood at $463.2 million (changed N/A YoY), and the FY2025 full-year result was $1.3 billion, up 24.2% from the prior year.
- Depreciation and Depletion for Q2 2015 stood at $216.6 million, up from $16.7 million in the prior quarter.
- The five-year high for Depreciation and Depletion was $216.6 million in Q2 2015, with the low at $13.6 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 139.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 216.60 Mn |
| Jun 30, 2015 | 216.60 Mn |
| Mar 31, 2015 | 16.70 Mn |
| Mar 31, 2015 | 16.70 Mn |
| Jun 30, 2014 | 216.30 Mn |
| Jun 30, 2014 | 216.30 Mn |
| Mar 31, 2014 | 13.60 Mn |
| Mar 31, 2014 | 13.60 Mn |